Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.
Identifieur interne : 003677 ( PubMed/Curation ); précédent : 003676; suivant : 003678Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.
Auteurs : Richard C. Dodel [Allemagne] ; Helmut Höffken ; J Carsten Möller ; Bernhard Bornschein ; Thomas Klockgether ; Thomas Behr ; Wolfgang H. Oertel ; Uwe SiebertSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
Descripteurs français
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Ambulatory Care Facilities (economics), Brain (radionuclide imaging), Cost-Benefit Analysis (statistics & numerical data), Decision Trees, Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Dopamine Plasma Membrane Transport Proteins, Germany, Health Care Costs (statistics & numerical data), Humans, Membrane Glycoproteins, Membrane Transport Proteins (analysis), National Health Programs (economics), Nerve Tissue Proteins, Neurologic Examination (economics), Parkinson Disease (economics), Parkinson Disease (radionuclide imaging), Prospective Payment System (economics), Referral and Consultation (economics), Tomography, Emission-Computed, Single-Photon (economics).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , analysis : Membrane Transport Proteins.
- chemical , diagnostic use : Dihydroxyphenylalanine.
- geographic : Germany, Membrane Glycoproteins, Nerve Tissue Proteins.
- economics : Ambulatory Care Facilities, National Health Programs, Neurologic Examination, Parkinson Disease, Prospective Payment System, Referral and Consultation, Tomography, Emission-Computed, Single-Photon.
- radionuclide imaging : Brain, Parkinson Disease.
- statistics & numerical data : Cost-Benefit Analysis, Health Care Costs.
- Decision Trees, Dopamine Plasma Membrane Transport Proteins, Humans.
Abstract
As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.
DOI: 10.1002/mds.10580
PubMed: 14531047
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003677
Links to Exploration step
pubmed:14531047Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</title>
<author><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C" last="Dodel">Richard C. Dodel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Friedrich-Wilhelms-University, Bonn</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hoffken, Helmut" sort="Hoffken, Helmut" uniqKey="Hoffken H" first="Helmut" last="Höffken">Helmut Höffken</name>
</author>
<author><name sortKey="Moller, J Carsten" sort="Moller, J Carsten" uniqKey="Moller J" first="J Carsten" last="Möller">J Carsten Möller</name>
</author>
<author><name sortKey="Bornschein, Bernhard" sort="Bornschein, Bernhard" uniqKey="Bornschein B" first="Bernhard" last="Bornschein">Bernhard Bornschein</name>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
</author>
<author><name sortKey="Behr, Thomas" sort="Behr, Thomas" uniqKey="Behr T" first="Thomas" last="Behr">Thomas Behr</name>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name>
</author>
<author><name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14531047</idno>
<idno type="pmid">14531047</idno>
<idno type="doi">10.1002/mds.10580</idno>
<idno type="wicri:Area/PubMed/Corpus">003677</idno>
<idno type="wicri:Area/PubMed/Curation">003677</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</title>
<author><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C" last="Dodel">Richard C. Dodel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Friedrich-Wilhelms-University, Bonn</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hoffken, Helmut" sort="Hoffken, Helmut" uniqKey="Hoffken H" first="Helmut" last="Höffken">Helmut Höffken</name>
</author>
<author><name sortKey="Moller, J Carsten" sort="Moller, J Carsten" uniqKey="Moller J" first="J Carsten" last="Möller">J Carsten Möller</name>
</author>
<author><name sortKey="Bornschein, Bernhard" sort="Bornschein, Bernhard" uniqKey="Bornschein B" first="Bernhard" last="Bornschein">Bernhard Bornschein</name>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
</author>
<author><name sortKey="Behr, Thomas" sort="Behr, Thomas" uniqKey="Behr T" first="Thomas" last="Behr">Thomas Behr</name>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name>
</author>
<author><name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ambulatory Care Facilities (economics)</term>
<term>Brain (radionuclide imaging)</term>
<term>Cost-Benefit Analysis (statistics & numerical data)</term>
<term>Decision Trees</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (diagnostic use)</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Germany</term>
<term>Health Care Costs (statistics & numerical data)</term>
<term>Humans</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins (analysis)</term>
<term>National Health Programs (economics)</term>
<term>Nerve Tissue Proteins</term>
<term>Neurologic Examination (economics)</term>
<term>Parkinson Disease (economics)</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Prospective Payment System (economics)</term>
<term>Referral and Consultation (economics)</term>
<term>Tomography, Emission-Computed, Single-Photon (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
<term>Membrane Glycoproteins</term>
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Ambulatory Care Facilities</term>
<term>National Health Programs</term>
<term>Neurologic Examination</term>
<term>Parkinson Disease</term>
<term>Prospective Payment System</term>
<term>Referral and Consultation</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Cost-Benefit Analysis</term>
<term>Health Care Costs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Decision Trees</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Humans</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14531047</PMID>
<DateCreated><Year>2003</Year>
<Month>10</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18 Suppl 7</Volume>
<PubDate><Year>2003</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</ArticleTitle>
<Pagination><MedlinePgn>S52-62</MedlinePgn>
</Pagination>
<Abstract><AbstractText>As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.</AbstractText>
<CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dodel</LastName>
<ForeName>Richard C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Höffken</LastName>
<ForeName>Helmut</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Möller</LastName>
<ForeName>J Carsten</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bornschein</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Klockgether</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Behr</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Oertel</LastName>
<ForeName>Wolfgang H</ForeName>
<Initials>WH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Siebert</LastName>
<ForeName>Uwe</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2C598205QX</RegistryNumber>
<NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>63-84-3</RegistryNumber>
<NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000554">Ambulatory Care Facilities</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003362">Cost-Benefit Analysis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D003663">Decision Trees</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004295">Dihydroxyphenylalanine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D050483">Dopamine Plasma Membrane Transport Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017048">Health Care Costs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008562">Membrane Glycoproteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009313">National Health Programs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011445">Prospective Payment System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012017">Referral and Consultation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>3</Month>
<Day>30</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14531047</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10580</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:14531047 |texte= Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:14531047" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |